Search Result

Results for "

relaxant effects

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (8) Akt (6) Apoptosis (6) Calcium Channel (2) Carbonic Anhydrase (1) Cholinesterase (ChE) (2) COX (1) Cytochrome P450 (1) Drug Derivative (2) Endogenous Metabolite (3) Environmental Pollutants (1) GABA Receptor (2) Histamine Receptor (1) iGluR (3) Isotope-Labeled Compounds (8) mAChR (2) NF-κB (5) Oxidative Phosphorylation (1) Parasite (1) PGC-1α (4) Phosphodiesterase (PDE) (2) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (6) Reference Standards (5) TGF-beta/Smad (6) Wnt (6) β-catenin (6)
By Research Areas:	Cancer (10) Cardiovascular Disease (9) Endocrinology (6) Inflammation/Immunology (7) Metabolic Disease (6) Neurological Disease (29)

By Targets:

5-HT Receptor (1)

Adrenergic Receptor (8)

Akt (6)

Apoptosis (6)

Calcium Channel (2)

Carbonic Anhydrase (1)

Cholinesterase (ChE) (2)

COX (1)

Cytochrome P450 (1)

Drug Derivative (2)

Endogenous Metabolite (3)

Environmental Pollutants (1)

GABA Receptor (2)

Histamine Receptor (1)

iGluR (3)

Isotope-Labeled Compounds (8)

mAChR (2)

NF-κB (5)

Oxidative Phosphorylation (1)

Parasite (1)

PGC-1α (4)

Phosphodiesterase (PDE) (2)

Platelet-activating Factor Receptor (PAFR) (1)

Potassium Channel (6)

Reference Standards (5)

TGF-beta/Smad (6)

Wnt (6)

β-catenin (6)

By Research Areas:

Cancer (10)

Cardiovascular Disease (9)

Endocrinology (6)

Inflammation/Immunology (7)

Metabolic Disease (6)

Neurological Disease (29)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0252

Hydrochlorothiazide Maximum Cited Publications 7 Publications Verification HCTZ	TGF-beta/Smad Potassium Channel	Cardiovascular Disease Metabolic Disease Cancer
Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B0194A

Tizanidine hydrochloride	Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI) .

HY-B0194

Tizanidine	Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI) .

HY-B0678

Metaxalone AHR438; NSC170959	NF-κB PGC-1α	Neurological Disease Inflammation/Immunology
Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia .

HY-157959

Orphenadrine (±)-Orphenadrine	iGluR Cytochrome P450 Cholinesterase (ChE)	Neurological Disease Cancer
Orphenadrine ((±)-Orphenadrine) is a skeletal muscle relaxant and NMDA antagonist that also has antiparkinsonian, antihistamine, antitremor, antispasmodic, and analgesic effects. Orphenadrine inhibits the binding of ^[3H]MK-801 to the phencyclidine (PCP) binding site of the NMDA receptor. Orphenadrine is also an anticholinergic and CYP2B inducer. Orphenadrine may exert pro-tumor effects, causing CAR nuclear translocation, resulting in microsomal reactive oxygen species (ROS) production and oxidative stress. Orphenadrine also exerts neuronal protection, protecting rat cerebellar granule cells (CGC) from 3-NPA-induced death and has inhibitory potential against neurodegenerative diseases mediated by NMDA receptor overactivation .

HY-118301

ADX71441	GABA Receptor 5-HT Receptor	Neurological Disease
ADX71441 is an orally active, blood-brain barrier penetrant positive allosteric modulator of GABA_B receptor. ADX71441 potentiates the activity of endogenous GABA at GABA_B receptor, with an EC₅₀ of 96 nM. ADX71441 functionally inhibits adenosine transporters and 5-HT_2B receptor. ADX71441 produces anxiolytic-like, analgesic, muscle relaxant, hypothermic and overactive bladder inhibitory effects, reduces acute locomotor activity levels, decreases voluntary intake of alcohol and saccharin, attenuates stress-induced neuronal activation, and exhibits anti-hyperalgesic activity .

HY-B2112

Valethamate bromide	mAChR	Neurological Disease
Valethamate bromide is an ester, serving as an effective rapidly acting anticholinergic antispasmodic and muscle relaxant. Valethamate bromide accelerates labor by improving cervical dilation. Valethamate bromide can significantly shorten the labor process and have fewer side effects .

HY-W016414

Triethyl phosphate	Environmental Pollutants Endogenous Metabolite	Cardiovascular Disease
Triethyl phosphate is a versatile phosphate ester compound. Triethyl phosphate induces rapid and short-acting anesthesia, and exhibits hypotensive, smooth muscle relaxant, and cardiac inhibitory effects. Triethyl phosphate also modulates cholinergic toxicity; its anesthetic effect shows sex- and age-dependency in rodents, and it interacts with SKF 525-A (HY-B1311) to alter the duration of anesthesia .

HY-B0252S1

Hydrochlorothiazid-13C,d2 HCTZ-¹³C,d₂	Isotope-Labeled Compounds TGF-beta/Smad Potassium Channel	Cardiovascular Disease Metabolic Disease
Hydrochlorothiazid- ¹³C,d₂ is the ¹³C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-137951

Metizolam	Drug Derivative	Neurological Disease
Metizolam, a thienotriazolodiazepine, is the demethylated analogue of Etizolam. Metizolam exhibits psychomotor stabilizing, anxiolytic, sedative, myo-relaxant and amnestic effects .

HY-B0252R

Hydrochlorothiazide (Standard) Maximum Cited Publications 7 Publications Verification HCTZ (Standard)	Reference Standards TGF-beta/Smad Potassium Channel	Cardiovascular Disease Metabolic Disease Cancer
Hydrochlorothiazide (Standard) is the analytical standard of Hydrochlorothiazide. This product is intended for research and analytical applications. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B1283

Mephenesin	iGluR	Neurological Disease
Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm .

HY-B0252S

Hydrochlorothiazid-d2 HCTZ-d₂	TGF-beta/Smad Potassium Channel	Cardiovascular Disease Metabolic Disease
Hydrochlorothiazid-d₂ is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-P3269

Calciseptine	Calcium Channel	Cardiovascular Disease
Calciseptine is a natural polypeptide toxin found in the venom of the black mamba snake (Dendroaspis p. polylepis). Calciseptine is a highly effective and selective blocker of the L-type channel of the Cav1.2 subtype, with an IC₅₀ value of 92 nM. Calciseptine has no effect on Cav3.1, Cav2.2, Cav2.1, Cav1.1, voltage-sensitive sodium channels and potassium channels. Calciseptine exhibits negative inotropic and negative relaxant effects on mice, and does not affect heart rate or the action potential of sinoatrial node pacemaker cells. Calciseptine can be used for research on cardiovascular diseases_[1].

HY-B0194S

Tizanidine-d4	Isotope-Labeled Compounds Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine-d₄ is the deuterium labeled Tizanidine (HY-B0194). Tizanidine, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-B0252S3

Hydrochlorothiazide-15N2,13C,d2 HCTZ-¹⁵N₂,¹³C,d₂	Potassium Channel TGF-beta/Smad Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease Cancer
Hydrochlorothiazide- ¹⁵N₂, ¹³C,d₂ is ¹⁵N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B1901S

Eperisone-d10 hydrochloride	Isotope-Labeled Compounds	Neurological Disease
Eperisone-d₁₀ (hydrochloride) is the deuterium labeled Eperisone hydrochloride. Eperisone Hydrochloride ((±)-Eperisone hydrochloride) is an antispastic agent used for treatment of diseases characterized by muscle stiffness and pain. It works by relaxing both skeletal muscles and vascularsmooth muscles, thus demonstrating avariety of effects such as reduction ofmyotonia, improvement of circulationand suppression of the pain reflex. Eperisone Hydrochloride ((±)-Eperisone hydrochloride) is a centrally acting muscle relaxant inhibiting the pain reflex pathway, having a vasodilator effect [2 .

HY-171253

Clotizolam	Platelet-activating Factor Receptor (PAFR)	Neurological Disease
Clotizolam is a thienobenzodiazepine derivative that has antagonistic activity against platelet-activating factor (PAF). Clotizolam possesses sedative, anxiolytic, anticonvulsant,and muscle relaxant effects .

HY-107276

Yubeinine	Others	Inflammation/Immunology
Yubeinine is an alkaloid with tracheal relaxant effects .

HY-14895B

Fabomotizole dihydrochloride CM346 dihydrochloride	Endogenous Metabolite	Neurological Disease
Fabomotizole dihydrochloride is an anxiolytic agent. Fabomotizole dihydrochloride produces anxiolytic and neuroprotective effects without any muscle relaxant actions.

HY-167650

Fletazepam	GABA Receptor	Neurological Disease
Fletazepam is a benzodiazepine derivative with sedative, anxiolytic and muscle relaxant effects. Fletazepam can be utilized in neurological research .

HY-14895R

Fabomotizole (Standard) CM346 (Standard)	Parasite Reference Standards	Neurological Disease
Fabomotizole (Standard) is the analytical standard of Fabomotizole. This product is intended for research and analytical applications. Fabomotizole (CM346) is an anxiolytic agent. Fabomotizole produces anxiolytic and neuroprotective effects without any muscle relaxant actions.

HY-119291

RA642	Phosphodiesterase (PDE)	Others
RA642 is a compound with vasodilatory and hypertensive effects, with the activity of increasing arterial blood pressure, enhancing cerebral blood flow, reducing cerebrovascular resistance and peripheral resistance, and having a papaverine-like relaxant effect on smooth muscle in anesthetized animals.

HY-117162

S 1432	Cholinesterase (ChE)	Neurological Disease
S 1432 is a central nervous system depressant with anticonvulsant and muscle relaxant effects. S 1432 significantly reduces acetylcholine levels in the striatum inhibits convulsions induced by pentylenetetrazol. S 1432 can be used in the development of psychotropic drugs .

HY-106885

F 2692	Drug Derivative	Neurological Disease
F 2692 is an orally effective derivative of pyridazine. F 2692 has significant anti anxiety effects. F 2692 also has activities such as anticonvulsant, sedative, and muscle relaxant. F 2692 can be used for research on neurological disorders such as anxiety disorders .

HY-126175

Neostigmine iodide	Endogenous Metabolite	Neurological Disease
Neostigmine iodide is a reversible acetylcholinesterase inhibitor with muscle tone-enhancing activity. Neostigmine iodide is primarily used to improve muscle function in patients with myasthenia gravis. Neostigmine iodide is also used in routine anesthesia to reverse the effects of nondepolarizing muscle relaxants such as rocuronium .

HY-124515

Dihexyverine hydrochloride	Histamine Receptor mAChR	Neurological Disease
Dihexyverine hydrochloride is a compound belonging to the amino alcohol ester class. Dihexyverine hydrochloride possesses anticholinergic, smooth muscle relaxant, antihistaminic, and antiemetic effects. Dihexyverine hydrochloride can also shorten the duration of labor. Dihexyverine hydrochloride can be used in research related to gastrointestinal spasms, obstetrics, and other fields .

HY-121670

Ambenoxan	Others	Neurological Disease
Ambenoxan is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.

HY-121670A

Ambenoxan hydrochloride	Adrenergic Receptor	Neurological Disease
Ambenoxan hydrochloride is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.

HY-B1283S

Mephenesin-d3	Isotope-Labeled Compounds iGluR	Neurological Disease
Mephenesin-d₃ is deuterium labeled Mephenesin. Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm .

HY-B0252S2

Hydrochlorothiazide-13C6 HCTZ-¹³C₆	TGF-beta/Smad Potassium Channel	Metabolic Disease
Hydrochlorothiazide- ¹³C₆ is the ¹³C labeled Hydrochlorothiazide . Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-174257

RCD405	NF-κB Oxidative Phosphorylation	Inflammation/Immunology
RCD405 is a bronchodilator. RCD405 exerts relaxant effects by acting directly on human airway smooth muscle (hASM) with an EC₅₀ value of 12 μM for histamine-induced contractions and 45.71 μM for carbachol-induced contractions. RCD405 inhibits cholinergic and histaminergic tone and reduces electrically stimulated (EFS)-induced contractions. RCD405 is promising for research of asthma and chronic obstructive pulmonary disease (COPD) .

HY-B0678S

Metaxalone-d3	Isotope-Labeled Compounds NF-κB PGC-1α	Neurological Disease Inflammation/Immunology
Metaxalone-d₃ is the deuterium labeled Metaxalone. Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia .

HY-B0678S1

Metaxalone-d6 AHR438-d₆; NSC170959-d₆	Isotope-Labeled Compounds NF-κB PGC-1α	Neurological Disease Inflammation/Immunology
Metaxalone-d₆ is deuterium labeled Metaxalone. Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia .

HY-B0678R

Metaxalone (Standard) AHR438 (Standard); NSC170959 (Standard)	Reference Standards NF-κB PGC-1α	Neurological Disease Inflammation/Immunology
Metaxalone (Standard) is the analytical standard of Metaxalone. This product is intended for research and analytical applications. Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia .

HY-B0194R

Tizanidine (Standard)	Reference Standards Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine (Standard) is the analytical standard of Tizanidine (HY-B0194). This product is intended for research and analytical applications. Tizanidine, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-B0194AR

Tizanidine hydrochloride (Standard)	Reference Standards Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine hydrochloride (Standard) is the analytical standard of Tizanidine hydrochloride (HY-B0194A). This product is intended for research and analytical applications. Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-B0194AS

Tizanidine-d4 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine-d₄ hydrochloride is deuterium labeled Tizanidine hydrochloride (HY-B0194A). Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-182426

NCX-278	Carbonic Anhydrase	Neurological Disease
NCX-278 is a human carbonic anhydrase inhibitor with a 13 nM K_i for hCA II, 410 nM K_i for hCA I, 181 nM K_i for hCA IV, and selective inhibition of hCA II over hCA IV. NCX-278 is a potent and effective stimulator of NO/sGC/cGMP signaling with an EC₅₀ of 2.05 lM. NCX-278 exerts NO-mediated vascular relaxant effects. NCX-278 lowers intraocular pressure in normotensive rabbits. NCX-278 can be used for the research of open-angle glaucoma .

HY-105203

MS-322	Others	Neurological Disease
MS-322 is an orally active centrally acting muscle relaxant. MS-322 can dose-dependently inhibit spinal reflex potentials, reduce neuronal excitability and muscle afferent discharges, and so on in rats. In addition, MS-322 has relatively weak inhibitory effects on other central nervous system pathways and no effect on the neuromuscular junction .

HY-P3269A

Calciseptine TFA	Calcium Channel	Cardiovascular Disease
Calciseptine TFA, a polypeptide found in black mamba venom, is a selcetive Cav1.2 L-type calcium channel inhibitor with an IC₅₀ of 92 nM. Calciseptine TFA binds to the pore domain shoulder at repeats III and IV of Cav1.2, stabilizing an inactivated conformation. Calciseptine TFA exhibits negative inotropic and negative relaxant effects on mice, and does not affect heart rate or the action potential of sinoatrial node pacemaker cells. Calciseptine TFA can be used for the research of cardiovascular diseases .

HY-19091

ICI-170777	Phosphodiesterase (PDE) Adrenergic Receptor COX	Cardiovascular Disease
ICI-170777 is an orally active cardiotonic agent and type III Phosphodiesterase inhibitor, with an IC₅₀ of 2.5 μM against cyclic AMP phosphodiesterase type III from canine cardiac fractions. ICI-170777 inhibits Aldrin epoxidase and pentobarbital metabolism. It enhances β-adrenergic receptor-mediated positive inotropic effects without causing chronotropic effects, while also exerting balanced arteriolar/venular vasodilator, platelet aggregation inhibitor and smooth muscle relaxant activities. ICI-170777 restores cardiac function in an acute canine heart failure model, exhibits additive effects when combined with Ouabain (HY-B1457), and shows no significant activity against multiple receptor classes or non-cardiac systems. ICI-170777 can be used in research related to congestive heart failure .

Cat. No.	Product Name	Target	Research Area

HY-P3269

Calciseptine	Calcium Channel	Cardiovascular Disease
Calciseptine is a natural polypeptide toxin found in the venom of the black mamba snake (Dendroaspis p. polylepis). Calciseptine is a highly effective and selective blocker of the L-type channel of the Cav1.2 subtype, with an IC₅₀ value of 92 nM. Calciseptine has no effect on Cav3.1, Cav2.2, Cav2.1, Cav1.1, voltage-sensitive sodium channels and potassium channels. Calciseptine exhibits negative inotropic and negative relaxant effects on mice, and does not affect heart rate or the action potential of sinoatrial node pacemaker cells. Calciseptine can be used for research on cardiovascular diseases_[1].

HY-P4013

[Arg15,20,21, Leu17] VIP-Gly-Lys-Arg-NH2	Peptides	Inflammation/Immunology
[Arg15,20,21, Leu17] VIP-Gly-Lys-Arg-NH2 is a vasoactive intestinal polypeptide (VIP) analog with relaxant effects .

HY-P3269A

Calciseptine TFA	Calcium Channel	Cardiovascular Disease
Calciseptine TFA, a polypeptide found in black mamba venom, is a selcetive Cav1.2 L-type calcium channel inhibitor with an IC₅₀ of 92 nM. Calciseptine TFA binds to the pore domain shoulder at repeats III and IV of Cav1.2, stabilizing an inactivated conformation. Calciseptine TFA exhibits negative inotropic and negative relaxant effects on mice, and does not affect heart rate or the action potential of sinoatrial node pacemaker cells. Calciseptine TFA can be used for the research of cardiovascular diseases .

Cat. No.	Product Name	Chemical Structure

HY-B0252S1

Hydrochlorothiazid-13C,d2

Hydrochlorothiazid- ¹³C,d₂ is the ¹³C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B0252S

Hydrochlorothiazid-d2

Hydrochlorothiazid-d₂ is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B0194S

Tizanidine-d4

Tizanidine-d₄ is the deuterium labeled Tizanidine (HY-B0194). Tizanidine, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-B0252S3

Hydrochlorothiazide-15N2,13C,d2

Hydrochlorothiazide- ¹⁵N₂, ¹³C,d₂ is ¹⁵N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B1901S

Eperisone-d10 hydrochloride

Eperisone-d₁₀ (hydrochloride) is the deuterium labeled Eperisone hydrochloride. Eperisone Hydrochloride ((±)-Eperisone hydrochloride) is an antispastic agent used for treatment of diseases characterized by muscle stiffness and pain. It works by relaxing both skeletal muscles and vascularsmooth muscles, thus demonstrating avariety of effects such as reduction ofmyotonia, improvement of circulationand suppression of the pain reflex. Eperisone Hydrochloride ((±)-Eperisone hydrochloride) is a centrally acting muscle relaxant inhibiting the pain reflex pathway, having a vasodilator effect [2 .

HY-B1283S

Mephenesin-d3
Mephenesin-d₃ is deuterium labeled Mephenesin. Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm .

HY-B0252S2

Hydrochlorothiazide-13C6

Hydrochlorothiazide- ¹³C₆ is the ¹³C labeled Hydrochlorothiazide . Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B0678S

Metaxalone-d3

Metaxalone-d₃ is the deuterium labeled Metaxalone. Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia .

HY-B0678S1

Metaxalone-d6

Metaxalone-d₆ is deuterium labeled Metaxalone. Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia .

HY-B0194AS

Tizanidine-d4 hydrochloride

Tizanidine-d₄ hydrochloride is deuterium labeled Tizanidine hydrochloride (HY-B0194A). Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks